Astria Therapeutics(US:ATXS) ZACKS·2025-09-09 14:55Core Viewpoint - Astria Therapeutics, Inc. (ATXS) shows significant upside potential with a mean price target of $29.33, indicating a 294.8% increase from its current trading price of $7.43 [1][12]. Price Targets and Analyst Consensus - The average price target for ATXS is based on nine short-term estimates, ranging from a low of $16.00 to a high of $49.00, with a standard deviation of $9.19, suggesting variability in analyst predictions [2]. - The lowest estimate indicates a potential increase of 115.3%, while the highest suggests an upside of 559.5% [2]. - A low standard deviation indicates strong agreement among analysts regarding the stock's price movement direction, which can serve as a starting point for further research [9]. Earnings Estimates and Analyst Optimism - Analysts have shown growing optimism regarding ATXS's earnings prospects, as evidenced by a positive trend in earnings estimate revisions, which correlates with near-term stock price movements [11]. - The Zacks Consensus Estimate for the current year has increased by 12.8% over the past month, with five estimates revised upward and no negative revisions [12]. - ATXS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for upside [13]. Caution on Price Targets - While price targets are a common tool for investors, they can often mislead, as empirical research shows that they rarely indicate actual stock price movements [7][10]. - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8].